Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509

Marathe, C.S.Jones, K.L.Rayner, C.K.Wu, T.Horowitz, M.2025-07-142025-07-142021Diabetes Care, 2021; 44(11):e194-e1950149-59921935-5548https://hdl.handle.net/2440/145901Comments and ResponsesAbstract unavailableen© 2021 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.Comments; Comments and Responses; Glucagon-Like Peptide 1 Receptor Agonist; Albiglutide; Prandial Insulin; Type 2 DiabetesHumansDiabetes Mellitus, Type 2InsulinHypoglycemic AgentsGlucagon-Like Peptide 1Glycemic ControlComment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509–2518Journal article10.2337/dc20-29872024-05-06592040Jones, K.L. [0000-0002-1155-5816]Rayner, C.K. [0000-0002-5527-256X]Wu, T. [0000-0003-1656-9210]Horowitz, M. [0000-0002-0942-0306]